All In Biotech

Drug Trial Radar · NCT06261840

Refining Treatment Options for Trichomonas Vaginalis Infection: A Comparative Analysis of Metronidazole and Secnidazole

Refining Treatment Options for Trichomonas Vaginalis Infection in Women and Men: A Comparative Analysis of Oral Multi-Dose Metronidazole and Single-Dose Secnidazole

Last checked: Nov 20, 2026Latest source record: May 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 1,200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,200

Planned (sponsor's estimate)

Start

May 6, 2025

Primary completion

May 1, 2029

Study completion Jul 31, 2029

Sponsor

Lead sponsor
Tulane UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Alabama at Birmingham; Louisiana State University Health Sciences Center in New Orleans; Healthcare Clinical Data
First posted
Feb 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a multi-centered, randomized, open-label, parallel, phase IV clinical trial comparing the effectiveness and cost-effectiveness of oral multi-dose metronidazole (MTZ) and oral single-dose secnidazole (SEC) for the treatment of Trichomonas vaginalis in both women and men.

Conditions

  • Trichomonas Vaginitis
  • Bacterial Vaginitis

Interventions

  • Metronidazole 500 mgDrug

    Multi-dose oral MTZ (500 mg twice daily for 7 days) for the treatment of T. vaginalis infection in women and men

  • Secnidazole 2000 MGDrug

    Single-dose 2 g oral SEC for the treatment of T. vaginalis infection in women and men

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment, as Measured by the Number of Participants that are Cured of Trichomonas Vaginalis at one month test of cure.Time frame: A TOC visit will be scheduled 4 weeks (+- 1 week) after post completion of treatment

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham [UAB] Gynecology Clinics

    Birmingham, Alabama · Recruiting

  • UAB Sexual Health Research Clinic [SHRC]

    Birmingham, Alabama · Recruiting

  • Segal Trials Healthcare Clinical Data, Inc. 1065 NE 125th St. Suite 417 North Miami, FL 33161

    North Miami, Florida · Not yet recruiting

  • LSU-CrescentCare Sexual Health Center

    New Orleans, Louisiana · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.